Hemogenyx Pharmaceuticals PLC Announces Institutional Investment
Hemogenyx Pharmaceuticals (LSE:HEMO) has secured institutional investment of £709,200 through the issuance of 394,000 new Ordinary Shares at £1.80 per share. The institutional investor will also receive one-for-two warrants, exercisable at £3.50 per share.
The funding will support the continuation of Phase I clinical trials for HG-CT-1, the company's Chimeric Antigen Receptor T-cell therapy targeting relapsed/refractory acute myeloid leukemia (R/R AML) in adults. The initial patient received HG-CT-1 treatment in February 2024, with plans to recruit a second patient pending satisfactory outcomes.
The new shares are expected to be admitted to trading on the Main Market of the London Stock Exchange around March 18, 2025. Following admission, the company's enlarged issued share capital will comprise 4,093,539 ordinary shares.
Hemogenyx Pharmaceuticals (LSE:HEMO) ha ottenuto un investimento istituzionale di £709,200 tramite l'emissione di 394,000 nuove Azioni Ordinarie a £1.80 per azione. L'investitore istituzionale riceverà anche un warrant per ogni due azioni, esercitabile a £3.50 per azione.
Il finanziamento supporterà la continuazione dei trial clinici di Fase I per HG-CT-1, la terapia con cellule T a recettore chimerico di antigeni dell'azienda, mirata alla leucemia mieloide acuta (R/R AML) recidivante/refrattaria negli adulti. Il primo paziente ha ricevuto il trattamento con HG-CT-1 a febbraio 2024, con piani per reclutare un secondo paziente in attesa di risultati soddisfacenti.
Le nuove azioni dovrebbero essere ammesse alla negoziazione sul Mercato Principale della Borsa di Londra intorno al 18 marzo 2025. Dopo l'ammissione, il capitale sociale emesso dell'azienda comprenderà 4,093,539 azioni ordinarie.
Hemogenyx Pharmaceuticals (LSE:HEMO) ha asegurado una inversión institucional de £709,200 a través de la emisión de 394,000 nuevas Acciones Ordinarias a £1.80 por acción. El inversor institucional también recibirá un warrant por cada dos acciones, que se podrá ejercer a £3.50 por acción.
El financiamiento apoyará la continuación de los ensayos clínicos de Fase I para HG-CT-1, la terapia con células T de receptor de antígeno quimérico de la compañía, dirigida a la leucemia mieloide aguda (R/R AML) en adultos que ha recaído/refractado. El primer paciente recibió el tratamiento con HG-CT-1 en febrero de 2024, con planes de reclutar un segundo paciente a la espera de resultados satisfactorios.
Se espera que las nuevas acciones sean admitidas a negociación en el Mercado Principal de la Bolsa de Valores de Londres alrededor del 18 de marzo de 2025. Tras la admisión, el capital social emitido de la empresa constará de 4,093,539 acciones ordinarias.
Hemogenyx Pharmaceuticals (LSE:HEMO)는 £709,200의 기관 투자를 확보했으며, 이는 주당 £1.80로 394,000개의 신규 보통주를 발행한 결과입니다. 기관 투자자는 또한 2주당 1개의 워런트를 받을 것이며, 이는 주당 £3.50에 행사할 수 있습니다.
이번 자금은 성인에서 재발성/내성 급성 골수성 백혈병(R/R AML)을 표적으로 하는 HG-CT-1에 대한 1상 임상 시험의 지속을 지원할 것입니다. 첫 번째 환자는 2024년 2월에 HG-CT-1 치료를 받았으며, 만족스러운 결과를 기다리며 두 번째 환자를 모집할 계획입니다.
새로운 주식은 2025년 3월 18일경 런던 증권 거래소의 주요 시장에서 거래될 것으로 예상됩니다. 상장 후, 회사의 확대된 발행 주식 자본은 4,093,539개의 보통주로 구성될 것입니다.
Hemogenyx Pharmaceuticals (LSE:HEMO) a sécurisé un investissement institutionnel de £709,200 grâce à l'émission de 394,000 nouvelles Actions Ordinaires à £1.80 par action. L'investisseur institutionnel recevra également un warrant pour deux actions, exerçable à £3.50 par action.
Le financement soutiendra la poursuite des essais cliniques de Phase I pour HG-CT-1, la thérapie par cellules T à récepteur d'antigène chimérique de l'entreprise, ciblant la leucémie myéloïde aiguë (R/R AML) récidivante/réfractaire chez les adultes. Le premier patient a reçu le traitement HG-CT-1 en février 2024, avec des plans pour recruter un deuxième patient en attente de résultats satisfaisants.
Les nouvelles actions devraient être admises à la négociation sur le Marché Principal de la Bourse de Londres autour du 18 mars 2025. Après l'admission, le capital social émis de l'entreprise comprendra 4,093,539 actions ordinaires.
Hemogenyx Pharmaceuticals (LSE:HEMO) hat eine institutionelle Investition in Höhe von £709,200 durch die Ausgabe von 394,000 neuen Stammaktien zu einem Preis von £1.80 pro Aktie gesichert. Der institutionelle Investor erhält außerdem einen Warrant für je zwei Aktien, der zu einem Preis von £3.50 pro Aktie ausgeübt werden kann.
Die Finanzierung wird die Fortsetzung der Phase I klinischen Studien für HG-CT-1 unterstützen, die zelluläre Therapie mit chimärem Antigenrezeptor des Unternehmens, die auf rezidivierende/refraktäre akute myeloische Leukämie (R/R AML) bei Erwachsenen abzielt. Der erste Patient erhielt die HG-CT-1-Behandlung im Februar 2024, und es sind Pläne zur Rekrutierung eines zweiten Patienten in Erwartung zufriedenstellender Ergebnisse in Arbeit.
Die neuen Aktien sollen voraussichtlich um den 18. März 2025 an der Hauptbörse der Londoner Börse gehandelt werden. Nach der Zulassung wird das ausgegebene Aktienkapital des Unternehmens aus 4,093,539 Stammaktien bestehen.
- Secured £709,200 in institutional investment
- Successful initiation of Phase I clinical trials with first patient treated
- Additional funding secured for clinical trial continuation
- Institutional investor confidence demonstrated through premium-priced warrants at £3.50
- Dilution of existing shareholders through new share issuance
Institutional backing of £709,200 for continuing Phase 1 Clinical Trials
LONDON, UNITED KINGDOM / ACCESS Newswire / March 11, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) ("Hemogenyx Pharmaceuticals" or the "Company") is pleased to announce that it was approached by an institution wishing to make an investment into the Company; this investor will subscribe £709,200 for the issue of 394,000 new Ordinary Shares (the "Subscription Shares") at £1.80 per share.
The subscribing institution will also receive a one-for-two warrant, exercisable at a price of £3.50 per share for each share subscribed (the "Warrants").
The net proceeds of this subscription will be dedicated to the continuation of the Phase I clinical trials for the Company's Chimeric Antigen Receptor T-cell therapy ("HG-CT-1"), aimed at treating relapsed/refractory acute myeloid leukemia in adults ("R/R AML"). As shareholders will be aware, the initial patient was infused with HG-CT-1 in February 2024 and, subject to a satisfactory outcome, a second patient will be recruited and treated as quickly as practical.
The Company will keep the market informed of future developments as trials proceed.
An application is being made to the Main Market of the London Stock Exchange, and admission of the Subscription Shares to trading is expected on or around 18 March 2025 ("Admission"). The Subscription Shares will rank pari passu with the Company's existing Ordinary Shares.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"We are very pleased with the progress of the clinical trials for our lead product, HG-CT-1.We are greatly encouraged by the confidence shown by the backing of the institution and are grateful for their support in advancing our mission to bring innovative treatments to patients with acute myeloid leukemia. This investment enables us to take a significant step forward with our HG-CT-1 program, moving further with clinical trials and bringing us closer to providing a new therapeutic option for patients facing this aggressive disease."
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 4,093,539 ordinary shares. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
FAQ
What is the size and price of Hemogenyx's (HOPHF) latest institutional investment in March 2025?
How will Hemogenyx (HOPHF) use the proceeds from the March 2025 investment?
What is the current status of Hemogenyx's (HOPHF) HG-CT-1 clinical trials?
When will Hemogenyx's (HOPHF) new subscription shares begin trading?
